How much did Hyundai Bioscience Co achieve in EBIT for the current year?
In the current year, Hyundai Bioscience Co has achieved an EBIT of -9.79 B KRW.
Hyundai Bioscience Co EBIT 2024
Hyundai Bioscience Co EBIT
-9.79 B KRW
Ticker
048410.KQ
ISIN
KR7048410005
In 2024, Hyundai Bioscience Co's EBIT was -9.79 B KRW, a -62.87% increase from the -26.35 B KRW EBIT recorded in the previous year.
The Hyundai Bioscience Co EBIT history
| YEAR | EBIT (undefined KRW) |
|---|---|
| 2023 | -9.79 |
| 2022 | -26.35 |
| 2021 | -9.77 |
| 2020 | -4.54 |
| 2019 | 2.56 |
| 2018 | 2.08 |
| 2017 | 1.46 |
| 2016 | -6.96 |
| 2015 | 1.36 |
| 2014 | 0.65 |
| 2013 | -8.35 |
| 2012 | -5.19 |
| 2011 | -14.64 |
| 2010 | -6.32 |
| 2009 | -10.07 |
| 2008 | -19.73 |
| 2007 | -14.44 |
| 2006 | -34.33 |
| 2005 | -15.55 |
| 2004 | -6.62 |
Hyundai Bioscience Co Revenue, EBIT, Net Income KR7048410005 ·
3 years
5 years
10 years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Hyundai Bioscience Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hyundai Bioscience Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hyundai Bioscience Co’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Hyundai Bioscience Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Hyundai Bioscience Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Hyundai Bioscience Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hyundai Bioscience Co’s growth potential.
Hyundai Bioscience Co Revenue, Profit, and EBIT History
| Date | Hyundai Bioscience Co Revenue | Hyundai Bioscience Co EBIT | Hyundai Bioscience Co Net Income |
|---|---|---|---|
| 2023 | 9.48 B KRW | -9.79 B KRW | -14.5 B KRW |
| 2022 | 7.85 B KRW | -26.35 B KRW | -15.81 B KRW |
| 2021 | 9.24 B KRW | -9.77 B KRW | -20.05 B KRW |
| 2020 | 12.51 B KRW | -4.54 B KRW | -8.61 B KRW |
| 2019 | 30.09 B KRW | 2.56 B KRW | 767 M KRW |
| 2018 | 31.24 B KRW | 2.08 B KRW | 2.62 B KRW |
| 2017 | 31.97 B KRW | 1.46 B KRW | 1.22 B KRW |
| 2016 | 36.1 B KRW | -6.96 B KRW | -8.07 B KRW |
| 2015 | 40.68 B KRW | 1.36 B KRW | 711 M KRW |
| 2014 | 28.91 B KRW | 647 M KRW | -3.11 B KRW |
| 2013 | 25.54 B KRW | -8.35 B KRW | -10.35 B KRW |
| 2012 | 37.08 B KRW | -5.19 B KRW | -7.96 B KRW |
| 2011 | 47.65 B KRW | -14.64 B KRW | -16.94 B KRW |
| 2010 | 85.27 B KRW | -6.32 B KRW | -8.06 B KRW |
| 2009 | 93.93 B KRW | -10.07 B KRW | -14.47 B KRW |
| 2008 | 118.88 B KRW | -19.73 B KRW | 5.26 B KRW |
| 2007 | 117.17 B KRW | -14.44 B KRW | 1.91 B KRW |
| 2006 | 228.83 B KRW | -34.33 B KRW | -98.57 B KRW |
| 2005 | 414.1 B KRW | -15.55 B KRW | -27.98 B KRW |
| 2004 | 567.06 B KRW | -6.62 B KRW | -5.07 B KRW |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 567.06 B KRW | -6.62 B KRW | -5.07 B KRW |
| 2005 | 414.1 B KRW | -15.55 B KRW | -27.98 B KRW |
| 2006 | 228.83 B KRW | -34.33 B KRW | -98.57 B KRW |
| 2007 | 117.17 B KRW | -14.44 B KRW | 1.91 B KRW |
| 2008 | 118.88 B KRW | -19.73 B KRW | 5.26 B KRW |
| 2009 | 93.93 B KRW | -10.07 B KRW | -14.47 B KRW |
| 2010 | 85.27 B KRW | -6.32 B KRW | -8.06 B KRW |
| 2011 | 47.65 B KRW | -14.64 B KRW | -16.94 B KRW |
| 2012 | 37.08 B KRW | -5.19 B KRW | -7.96 B KRW |
| 2013 | 25.54 B KRW | -8.35 B KRW | -10.35 B KRW |
| 2014 | 28.91 B KRW | 647 M KRW | -3.11 B KRW |
| 2015 | 40.68 B KRW | 1.36 B KRW | 711 M KRW |
| 2016 | 36.1 B KRW | -6.96 B KRW | -8.07 B KRW |
| 2017 | 31.97 B KRW | 1.46 B KRW | 1.22 B KRW |
| 2018 | 31.24 B KRW | 2.08 B KRW | 2.62 B KRW |
| 2019 | 30.09 B KRW | 2.56 B KRW | 767 M KRW |
| 2020 | 12.51 B KRW | -4.54 B KRW | -8.61 B KRW |
| 2021 | 9.24 B KRW | -9.77 B KRW | -20.05 B KRW |
| 2022 | 7.85 B KRW | -26.35 B KRW | -15.81 B KRW |
| 2023 | 9.48 B KRW | -9.79 B KRW | -14.5 B KRW |
Hyundai Bioscience Co stock margins KR7048410005 ·
The Hyundai Bioscience Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hyundai Bioscience Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hyundai Bioscience Co.
3 years
5 years
10 years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Hyundai Bioscience Co's sales revenue. A higher gross margin percentage indicates that the Hyundai Bioscience Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Hyundai Bioscience Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Hyundai Bioscience Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hyundai Bioscience Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hyundai Bioscience Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hyundai Bioscience Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Hyundai Bioscience Co Margin History
| Hyundai Bioscience Co Gross margin | Hyundai Bioscience Co Profit margin | Hyundai Bioscience Co EBIT margin | Hyundai Bioscience Co Profit margin |
|---|---|---|---|
| 2023 | 53.17 % | -103.2 % | -152.92 % |
| 2022 | 34.17 % | -335.65 % | -201.33 % |
| 2021 | 38.1 % | -105.72 % | -216.97 % |
| 2020 | 52.46 % | -36.29 % | -68.8 % |
| 2019 | 46.94 % | 8.49 % | 2.55 % |
| 2018 | 45.93 % | 6.66 % | 8.38 % |
| 2017 | 46.38 % | 4.58 % | 3.81 % |
| 2016 | 33.24 % | -19.29 % | -22.35 % |
| 2015 | 29.96 % | 3.33 % | 1.75 % |
| 2014 | 29.77 % | 2.24 % | -10.75 % |
| 2013 | 21.88 % | -32.69 % | -40.54 % |
| 2012 | 24.69 % | -14.01 % | -21.46 % |
| 2011 | 18.18 % | -30.72 % | -35.54 % |
| 2010 | 21.04 % | -7.41 % | -9.45 % |
| 2009 | 12.42 % | -10.72 % | -15.4 % |
| 2008 | 6.55 % | -16.6 % | 4.42 % |
| 2007 | 6.95 % | -12.32 % | 1.63 % |
| 2006 | 3.57 % | -15 % | -43.08 % |
| 2005 | 9.11 % | -3.75 % | -6.76 % |
| 2004 | 9.57 % | -1.17 % | -0.89 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 9.57 % | -1.17 % | -0.89 % |
| 2005 | 9.11 % | -3.75 % | -6.76 % |
| 2006 | 3.57 % | -15 % | -43.08 % |
| 2007 | 6.95 % | -12.32 % | 1.63 % |
| 2008 | 6.55 % | -16.6 % | 4.42 % |
| 2009 | 12.42 % | -10.72 % | -15.4 % |
| 2010 | 21.04 % | -7.41 % | -9.45 % |
| 2011 | 18.18 % | -30.72 % | -35.54 % |
| 2012 | 24.69 % | -14.01 % | -21.46 % |
| 2013 | 21.88 % | -32.69 % | -40.54 % |
| 2014 | 29.77 % | 2.24 % | -10.75 % |
| 2015 | 29.96 % | 3.33 % | 1.75 % |
| 2016 | 33.24 % | -19.29 % | -22.35 % |
| 2017 | 46.38 % | 4.58 % | 3.81 % |
| 2018 | 45.93 % | 6.66 % | 8.38 % |
| 2019 | 46.94 % | 8.49 % | 2.55 % |
| 2020 | 52.46 % | -36.29 % | -68.8 % |
| 2021 | 38.1 % | -105.72 % | -216.97 % |
| 2022 | 34.17 % | -335.65 % | -201.33 % |
| 2023 | 53.17 % | -103.2 % | -152.92 % |
Hyundai Bioscience Co Aktienanalyse
What does Hyundai Bioscience Co do?
Hyundai Bioscience Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Hyundai Bioscience Co's EBIT
Hyundai Bioscience Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Hyundai Bioscience Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Hyundai Bioscience Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Hyundai Bioscience Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Hyundai Bioscience Co Stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Hyundai Bioscience Co.
How has the EBIT of Hyundai Bioscience Co developed in recent years?
The EBIT of Hyundai Bioscience Co has increased by -62.871% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Hyundai Bioscience Co?
The EBIT of Hyundai Bioscience Co is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Hyundai Bioscience Co pay?
Over the past 12 months, Hyundai Bioscience Co paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hyundai Bioscience Co is expected to pay a dividend of 0 KRW.
What is the dividend yield of Hyundai Bioscience Co?
The current dividend yield of Hyundai Bioscience Co is .
When does Hyundai Bioscience Co pay dividends?
Hyundai Bioscience Co pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Hyundai Bioscience Co?
Hyundai Bioscience Co paid dividends every year for the past 0 years.
What is the dividend of Hyundai Bioscience Co?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is Hyundai Bioscience Co located?
Hyundai Bioscience Co is assigned to the 'Non-cyclical consumption' sector.
Wann musste ich die Aktien von Hyundai Bioscience Co kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Hyundai Bioscience Co from 4/13/2004 amounting to 50 KRW, you needed to have the stock in your portfolio before the ex-date on 12/29/2003.
When did Hyundai Bioscience Co pay the last dividend?
The last dividend was paid out on 4/13/2004.
What was the dividend of Hyundai Bioscience Co in the year 2023?
In the year 2023, Hyundai Bioscience Co distributed 0 KRW as dividends.
In which currency does Hyundai Bioscience Co pay out the dividend?
The dividends of Hyundai Bioscience Co are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Hyundai Bioscience Co
Our stock analysis for Hyundai Bioscience Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hyundai Bioscience Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
- Hyundai Bioscience Co Revenue
- Hyundai Bioscience Co Net Income
- Hyundai Bioscience Co P/E
- Hyundai Bioscience Co P/S
- Hyundai Bioscience Co EBIT
- Hyundai Bioscience Co Dividend
- Hyundai Bioscience Co Stocks
- Hyundai Bioscience Co Market capitalization
- Hyundai Bioscience Co Debt
- Hyundai Bioscience Co Liabilities
- Hyundai Bioscience Co Equity
- Hyundai Bioscience Co AAQS
- Hyundai Bioscience Co Employees
- Hyundai Bioscience Co ROE
- Hyundai Bioscience Co ROA
- Hyundai Bioscience Co ROCE